The global interleukin inhibitors market size was valued at USD 32.64 billion in 2024 and is expected to reach USD 85.51 billion by 2032, growing at a CAGR of 13.4% during the forecast period.
This growth is driven by factors such as the rising prevalence of autoimmune and chronic inflammatory diseases, increasing awareness and adoption of biologic therapies, and continuous advancements in targeted immunotherapy.
1 vista